secukinumab (Cosentyx)

following a full submission:

secukinumab (Cosentyx®) is accepted for restricted use within NHS Scotland.

Indication under review: alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

SMC restriction: Use in patients whose disease has not responded to adequate trials of at least two standard DMARDs either individually or in combination.

In phase III, randomised, placebo-controlled studies in patients with active psoriatic arthritis, a significantly greater proportion of patients who received secukinumab achieved at least 20% improvement in the American College of Rheumatology response criteria (ACR20) at 24 weeks compared with those who received placebo.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of secukinumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.